0000950123-20-005061.txt : 20200515 0000950123-20-005061.hdr.sgml : 20200515 20200515080029 ACCESSION NUMBER: 0000950123-20-005061 CONFORMED SUBMISSION TYPE: 13F-HR PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20200331 FILED AS OF DATE: 20200515 DATE AS OF CHANGE: 20200515 EFFECTIVENESS DATE: 20200515 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Bain Capital Life Sciences Investors, LLC CENTRAL INDEX KEY: 0001703031 IRS NUMBER: 813996001 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 13F-HR SEC ACT: 1934 Act SEC FILE NUMBER: 028-18477 FILM NUMBER: 20880650 BUSINESS ADDRESS: STREET 1: 200 CLARENDON STREET CITY: BOSTON STATE: MA ZIP: 02116 BUSINESS PHONE: 6175162878 MAIL ADDRESS: STREET 1: 200 CLARENDON STREET CITY: BOSTON STATE: MA ZIP: 02116 13F-HR 1 primary_doc.xml 13F-HR LIVE 0001703031 XXXXXXXX 03-31-2020 03-31-2020 false Bain Capital Life Sciences Investors, LLC

200 Clarendon Street Boston MA 02116

13F HOLDINGS REPORT 028-18477 Y Bain Capital Life Sciences Investors, LLC is (i) the general partner of Bain Capital Life Sciences Partners, LP, which is the general partner of Bain Capital Life Sciences Fund, L.P. and (ii) the general partner of BC SW, LP. The shares of common stock of Dynavax Technologies Corporation ("DVAX") included on the Information Table are as reported on the Schedule 13D filed by Bain Capital Life Sciences Fund, L.P. and BCIP Life Sciences Associates, LP on March 12, 2020 and reflect the exercise and conversion, as applicable, of securities convertible into or exercisable for shares of DVAX common stock held by such persons, after giving effect to the provisions of such securities that prevent the exercise or conversion of such securities if such persons would beneficially own more than 9.99% of the outstanding DVAX common stock following such exercise or conversion. As of March 31, 2020, such persons held an aggregate of 7,525,000 shares of DVAX common stock. The shares of common stock of Savara Inc ("SVRA") included on the Information Table are as reported on the Schedule 13D filed by Bain Capital Life Sciences Fund II, L.P. and BCIP Life Sciences Associates, LP on December 30, 2019 and reflect the exercise and conversion, as applicable, of securities convertible into or exercisable for shares of SVRA common stock held by such persons, after giving effect to the provisions of such securities that prevent the exercise or conversion of such securities if such persons would beneficially own more than 9.99% of the outstanding SVRA common stock following such exercise or conversion. As of March 31, 2020, such persons held an aggregate of 4,571,139 shares of SVRA common stock. The shares of common stock of X4 Pharmaceuticals, Inc. ("XFOR") included on the Information Table are as reported on the Schedule 13G filed by Bain Capital Life Sciences Fund, L.P., Bain Capital Life Sciences Fund II, L.P. and BCIP Life Sciences Associates, LP on December 9, 2019 and reflect the exercise and conversion, as applicable, of securities convertible into or exercisable for shares of XFOR common stock held by such persons, after giving effect to the provisions of such securities that prevent the exercise or conversion of such securities if such persons would beneficially own more than 9.99% of the outstanding XFOR common stock following such exercise or conversion. As of March 31, 2020, such persons held an aggregate of 1,250,000 shares of XFOR common stock. Adam Koppel 617-516-2000 /s/ Adam Koppel Boston MA 05-15-2020 3 11 591296 false 1 028-18476 Bain Capital Life Sciences Partners, LP 2 028-18478 Bain Capital Life Sciences Fund, LP 3 BC SW, LP INFORMATION TABLE 2 521.xml INFORMATION TABLE FOR FORM 13F DICERNA PHARMACEUTICALS INC COM 253031108 74954 4080237 SH SOLE 4080237 0 0 MARINUS PHARMACEUTICALS INC COM 56854Q101 12064 5942735 SH SOLE 5942735 0 0 REPLIMUNE GROUP INC COM 76029N106 28305 2838968 SH SOLE 2838968 0 0 SOLID BIOSCIENCES INC COM 83422E105 9252 3871164 SH SOLE 3871164 0 0 APTINYX INC COM 03836N103 12006 5558425 SH SOLE 5558425 0 0 SPRINGWORKS THERAPEUTICS INC COM 85205L107 196595 7281307 SH SOLE 7281307 0 0 DYNAVAX TECHNOLOGIES CORP. COM 268158201 30819 8730707 SH SOLE 8730707 0 0 CONSTELLATION PHARMACEUTICALS INC. COM 210373106 69257 2203529 SH SOLE 2203529 0 0 X4 PHARMACEUTICALS INC COM 98420X103 16485 1648485 SH SOLE 1648485 0 0 SAVARA INC COM 805111101 22976 5128593 SH SOLE 5128593 0 0 ARCUTIS BIOTHERAPEUTICS, INC. COM 03969K108 118583 3979292 SH SOLE 3979292 0 0